Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2011 Aug 11;71(3):383-5.
doi: 10.1016/j.neuron.2011.07.018.

Tracking down the molecular substrates of stress: new roles for p38α MAPK and kappa-opioid receptors

Affiliations
Comment

Tracking down the molecular substrates of stress: new roles for p38α MAPK and kappa-opioid receptors

John W Muschamp et al. Neuron. .

Abstract

In this issue, Bruchas et al. (2011) uncover a novel stress-induced p38α MAPK signaling cascade within serotonergic neurons of the dorsal raphe nucleus that mediates depressive and drug-seeking behaviors. Their findings have potentially important implications for medication development.

PubMed Disclaimer

Figures

None
Highly simplified schematic depicting a molecular cascade by which stress produces depressive effects via processes occurring within the dorsal raphe nucleus (DRN). Stressors such as social defeat stress (SDS) cause release of corticotropin-releasing factor (CRF), which in turn activates dynorphin-containing inputs to the DRN. Dynorphin stimulation of kappa-opioid receptors (KORs) activates (phosphorylates [P]) p38α MAPK, a crucial mediator of dysphoric (aversive) states. One down-stream consequence of p38α MAPK is translocation of SERT to neuronal membranes, which decreases extracellular concentrations of serotonin (5-HT) and alters stimulation of serotonin receptors (5HTRs). This hyposerotonergic state likely affects output to the prefrontal cortex (PFC), an element of mesocorticolimbic circuits implicated in motivation and emotion. Based on Bruchas et al., 2011 and Meloni et al., 2008, and Carlezon and Thomas, 2009.

Comment on

References

    1. Bruchas MR, Schindler AG, Shankar H, Messinger DI, Miyatake M, Land BB, Lemos JC, Hagan C, Neumaier JF, Quintana A, et al. Neuron. 2011 this issue. - PMC - PubMed
    1. Bruchas MR, Chavkin C. Psychopharmacol. 2010;210:137–147. - PMC - PubMed
    1. Carlezon WA, Jr, Béguin C, Knoll AT, Cohen BM. Pharmacol Ther. 2009;123:334–343. - PMC - PubMed
    1. Carlezon WA, Jr, Thomas M. Neuropharmacol. 2009;56(Suppl 1):122–132. - PMC - PubMed
    1. Duman RS, Monteggia LM. Biol Psychiatry. 2006;59:1116–1127. - PubMed

LinkOut - more resources